Nizam's Institute of Medical Sciences | Neurology Department

Research site

(Unclaimed)

Location

Millennium Block, Ground Floor, Panjagutta, Hyderabad, Telangana, India

Site insights

Top conditions

Top treatments

Safinamide

Dabigatran Etexilate

Warfarin

Nintedanib

Semaglutide

Dabigatran

Eteplirsen

MOTION

LY3537982

Letrozole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 31 total trials

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: Pemetrexed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling

Breast Neoplasms

Drug: Anastrozole

Drug: Tamoxifen

Status recently updated

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Active, not recruiting

Systemic Lupus Erythematosus

Other: Placebo

Drug: Deucravacitinib

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Part 1 (dose escalation) will evaluate the safety and tolerability of 2 doses (100 milligrams/kilogram \[mg/kg\] and 200 mg/kg) of eteplirsen in appr...

Active, not recruiting

Muscular Dystrophy, Duchenne

Drug: Eteplirsen

Locations recently updated

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Active, not recruiting

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)